Merus N.V. MRUS
We take great care to ensure that the data presented and summarized in this overview for Merus N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRUS
View all-
Rtw Investments, LP New York, NY4.17MShares$188 Million2.86% of portfolio
-
Commodore Capital LP New York, NY3.87MShares$175 Million16.32% of portfolio
-
Wellington Management Group LLP Boston, MA3.5MShares$158 Million0.03% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.97MShares$134 Million3.1% of portfolio
-
Samlyn Capital, LLC New York, NY2.67MShares$120 Million1.81% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.13MShares$95.8 Million1.3% of portfolio
-
Franklin Resources Inc San Mateo, CA1.98MShares$89.4 Million0.02% of portfolio
-
Holocene Advisors, LP New York, NY1.88MShares$84.7 Million0.27% of portfolio
-
Polar Capital Holdings PLC London, X01.71MShares$76.9 Million0.44% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY1.69MShares$76.2 Million2.71% of portfolio
Latest Institutional Activity in MRUS
Top Purchases
Top Sells
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Insider Transactions at MRUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Sven Ante Lundberg President, CEO & PEO |
BUY
Bona fide gift
|
Indirect |
40,601
+50.0%
|
-
|
|
Feb 19
2025
|
Sven Ante Lundberg President, CEO & PEO |
SELL
Bona fide gift
|
Direct |
40,601
-100.0%
|
-
|
|
Feb 13
2025
|
Sven Ante Lundberg President, CEO & PEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,372
+28.74%
|
$392,928
$24.43 P/Share
|
|
Aug 21
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
2,500
-26.31%
|
$135,000
$54.0 P/Share
|
|
Aug 21
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+20.83%
|
-
|
|
Aug 20
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
2,500
-26.31%
|
$135,000
$54.0 P/Share
|
|
Aug 20
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+20.83%
|
-
|
|
Jun 27
2024
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$600,000
$60.0 P/Share
|
|
Jun 27
2024
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+46.35%
|
$170,000
$17.94 P/Share
|
|
Jun 17
2024
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
62,000
-100.0%
|
$3,472,000
$56.52 P/Share
|
|
Jun 17
2024
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
62,000
+28.33%
|
$1,302,000
$21.92 P/Share
|
|
Jun 12
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
7,300
-51.04%
|
$416,100
$57.84 P/Share
|
|
Jun 12
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,300
+11.18%
|
-
|
|
Jun 10
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
1,000
-12.5%
|
$53,000
$53.22 P/Share
|
|
Jun 10
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.06%
|
-
|
|
Jun 04
2024
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
6,000
-27.08%
|
$312,000
$52.98 P/Share
|
|
Jun 04
2024
|
Harry Shuman VP Controller, PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+11.06%
|
-
|
|
Dec 19
2023
|
Harry Shuman VP Controller, PAO |
SELL
Open market or private sale
|
Direct |
115
-1.62%
|
$2,990
$26.68 P/Share
|
|
Dec 15
2023
|
Peter B. Silverman COO & GC |
SELL
Open market or private sale
|
Direct |
22,386
-100.0%
|
$559,650
$25.0 P/Share
|
|
Dec 15
2023
|
Peter B. Silverman COO & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
22,386
+27.72%
|
-
|
Last 12 Months Summary
| Bona fide gift | 40.6K shares |
|---|---|
| Exercise of conversion of derivative security | 108K shares |
| Bona fide gift | 40.6K shares |
|---|---|
| Open market or private sale | 91.3K shares |